Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10065


We hypothesize that 18FDG Positron Emission Tomography (FDG PET) imaging, carried out after the first cycle of chemotherapy, will identify responders, thus permitting early termination of potential toxic therapy in non- responders leading to a significant decrease in morbidity and cost. The value of PET imaging as an early predictor of response to chemotherapy has been shown in other cancers.


Inclusion Criteria: - Histologically proven ovarian cancer at diagnosis of any stage. - Patients with evidence of disease that is radiographically measurable (CT scan) - Patients have planned to undergo standard chemotherapy. Dose and schedule will be determined per treating physician Exclusion Criteria: - Patients with any other malignancy active within 5 years except for non-melanoma skin cancer, or carcinoma in situ of the cervix. - Patients with an active infection - Patients of childbearing potential are excluded from this study. - Patients who have expected survival < 3 months. - Patients not planning or able to receive the outlined chemotherapy regimen as part of standard practice. - Patient unable to complete study



Primary Contact:

Principal Investigator
Neeta Pandit-Taskar, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10065
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.